NUVL
$94.77-2.29 (-2.36%)
Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer.
Recent News
FDA Review of Zidesamtinib Data Might Change The Case For Investing In Nuvalent (NUVL)
Nuvalent, Inc. recently reported new clinical and preclinical data for its investigational ROS1-selective inhibitor zidesamtinib at the AACR 2026 meeting, alongside confirmation that the FDA has accepted its NDA to treat previously ROS1 TKI-treated adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer, with a PDUFA action date set for September 18, 2026. This combination of fresh efficacy and brain penetrance data with a formal regulatory review timeline marks a...
This Investor Sold $104 Million of Nuvalent Stock Amid Cancer Drug Developer's Nearly 30% Rally
Nuvalent develops targeted therapies for drug-resistant cancers, advancing clinical-stage candidates in precision oncology.
This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision
Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.
Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug
Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.
Praxis Stock Has Surged 700% in a Year, and This Fund Is Betting $266 Million on Its Pipeline
Praxis Precision Medicines develops therapies for central nervous system disorders, targeting unmet needs in neurology and psychiatry.